Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 71 publications.

Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, Andrews E. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-26. doi: 10.1002/pds.5103

Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0

Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2020 Feb;36(2):244-51. doi: 10.1002/jbmr.4188

Midkiff K, Harris D, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Results of a long-term postmarketing case series of adult osteosarcoma and teriparatide in the United States. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):688. doi: 10.1002/pds.4864

Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, Andrews E. Assessing the incidence of osteosarcoma among teriparatide users via linkage of data from Medicare Part D and multiple state cancer registries in the United States. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):683.

Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, Andrews E. Results from a fifteen-year postmarketing drug safety study of adult osteosarcoma and teriparatide in the US. Poster presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.

Harris D, Casso D, Midkiff K, Anderson A, Gilsenan A, Oliveria A, Andrews E, Kellier-Steele N. Methods, results, and lessons learned from two postmarketing drug safety surveillance studies linking state cancer registry data to large pharmacy databases. Presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8

Harris D, Midkiff K, Gilsenan A, Andrews E. Linking big (federal) data to state cancer registry data for a post-marketing drug safety surveillance study: challenges and lessons learned. Presented at the 2018 Annual Conference of the North American Association of Central Cancer Registries (NAACCR); June 12, 2018. Pittsburgh, PA.

Midkiff K, Andrews EB, Gilsenan A, Harris D. Comparing strategies to monitor for a potential association between teriparatide and adult osteosarcoma. Poster presented at the 10th Asian Conference on Pharmacoepidemiology (ACPE); October 31, 2017. Brisbane, Australia.

Harris D, Midkiff K, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the US. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):314. Previously presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). doi: 10.1002/pds

Harris D, Midkiff K, Gilsenan A, Andrews E. Twelve-year study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the U.S. Poster presented at the North American Association of Central Cancer Registries (NAACCR) 2017 Annual Conference; June 21, 2017. Albuquerque, NM.

Johannes CB, McQuay LJ, Midkiff KD, Calingaert B, Andrews EB, Tennis P, Brown JS, Camargo, Jr CA, DiSantostefano R, Rothman KJ, Sturmer T, Lanes S, Davis KJ. The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):446-58. doi: 10.1002/pds.4151

Andrews EB, Gilsenan A, Midkiff K, Harris D. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma - Editorial. Ann Epidemiol. 2016 Nov;26(11):751-3. doi: 10.1016/j.annepidem.2016.08.011

Midkiff KD, Andrews EB, Gilsenan AW, Deapen M, Harris DH, Schymura MJ, Hornicek FJ. The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):960-8. doi: 10.1002/pds.4008

Harris D, Midkiff K, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the United States. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):437-8.

Kellier-Steele N, Gilsenan A, Midkiff K, Harris D, Andrews E. Complementary observational studies assessing the incidence of a rare cancer outcome by linking state cancer registry data to large pharmacy claims databases in the United States. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):152.

Kellier-Steele N, Gilsenan A, Midkiff K, Harris D, Andrews E, Acquavella J. Parallel observational studies in a post-marketing setting assessing the incidence of osteosarcoma among teriparatide users versus a comparator group of nonusers by linking state cancer registry data to data from two large pharmacy claims databases. Poster presented at the North American Association of Central Cancer Registries (NAACCR) 2016 Annual Conference; June 14, 2016. St. Louis, MO.

Kellier-Steele N, Krohn K, Midkiff K, Harris D, Andrews E. Post-marketing case series study of adult osteosarcoma and for(s)teo: study update from the first 12 years. Poster presented at the 22nd Annual Meeting of the International Society of Clinical Densitometry (ISCD); June 1, 2016. Galway, Ireland.

Midkiff K, Harris D, Gilsenan A, Andrews E. Studying cancer as an adverse outcome from nononcological therapies: review of the Food and Drug Administration's postmarketing commitment database. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Midkiff KD, Andrews EB, Gilsenan AW, Harris DH. "First in Flight" or "When Pigs Fly" – Can cancer registries play a critical role at the national level in studying cancer as an adverse outcome from drug treatments? Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC.

Midkiff KD, Gilsenan AW, Andrews EB, Masica D, Ceberg J, Alvegard T. Findings from the postmarketing adult osteosarcoma surveillance study in the Nordic countries. Poster presented at the 37th Meeting of the Scandinavian Sarcoma Group; May 20, 2015. Stockholm, Sweden.

Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z

Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.

Midkiff KD, Von Scheele BG, Gilsenan AW, Ceberg J, Alvegård T. Progress update for the postmarketing adult osteosarcoma surveillance study in five Nordic countries. Poster presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.

Midkiff K, Johannes C, Tennis P, Calingaert B, McQuay L, Harris DH, Andrews E. Identifying causes of death in a large cohort of asthma patients. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):300.

Harris DH, Midkiff K, Gilsenan A, Kellier N, Masica D, Andrews E. Eight-year results from the US osteosarcoma surveillance study. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal.

Johannes C, McQuay L, Tennis P, Camargo CA, Schatz M, Midkiff K, Lanes S, DiSantostefano R, Davis K. Characteristics of initiators of asthma maintenance medications in 10 health care populations. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):273-4.

Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Kellier N, Masica D. Approaches to long-term surveillance for rare cancer events. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2013. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):218-9.

Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.

Midkiff KD, Harris DH, Gilsenan AW, Powell GL. Variations among cancer registries in accessing patients for a drug safety surveillance study. Poster presented at the NAACCR; June 2013.

Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.

Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768

Midkiff K, Calingaert B, Tennis P, Harris DH, Andrews EB. Using an automated computer-based algorithm to increase the efficiency of selecting the best match from national death index linkage results. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona. [abstract] Pharmacoepidemiol Drug Saf. 2012 Sep 5; 21(Suppl 3):S396.

Gilsenan A, Harris DH, Midkiff K, Wright J, Andrews E. Linking with multiple state cancer registries for safety surveillance study – Is it feasible? Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Midkiff KD, Harris D, Gilsenan AW, Wu Y, Andrews EB. Drug safety studies using cancer registry data: confluence of elements impacting the interview response rate. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S231. doi: 10.1002/pds.2206

Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.

Andrews EB, Midkiff KD, Gilsenan AW, Harris DH. Collaboration with multiple state cancer registries for a data linkage drug safety surveillance study – yes you can!. Poster presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Midkiff KD, Gilsenan AW, Harris DH, Wu Y, Masica D, Andrews EB. Exposure to possible osteosarcoma risk factors in a US postmarketing osteosarcoma surveillance study. Poster presented at the Scandinavian Sarcoma Group Annual Meeting; 2011.

Johannes CB, Varas-Lorenzo C, McQuay L, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Sep 1;19(9):881-8.

Midkiff K, Gilsenan A, Wu Y, Masica D, Andrews E. Characteristics of adult osteosarcoma patients: results from an ongoing post-marketing drug safety surveillance study. Poster presented at the American Society of Clinical Oncology; August 30, 2010.

Gilsenan AW, Andrews EB, Midkiff KD, Ladner A. Charting a new course in long-term safety: the critical role of cancer registries. Poster presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(Suppl 1):S116.

Harris DH, Midkiff KD, Gilsenan AW, Andrews EB. Public health surveillance collaboration: establishing a linkage algorithm with cancer registries for the Forteo Patient Registry. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2010.

Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica D, Andrews EB. The impact of patient access on post marketing drug safety studies using cancer registry data. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 14; 18(Suppl 1):S169. doi: 10.1002/pds.1806

Varas-Lorenzo C, Johannes C, McQuay L, Midkiff K, Stang MR, Fife D. Validation of serious ventricular arrhythmias in an administrative database. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(S1-273):S222.

Gilsenan AW, Andrews EB, Martin R, Midkiff KD. Charting a new course: the critical role of cancer registries in the science of drug safety. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.

Midkiff KD, Gilsenan AW, Martin RD, Andrews EB, Wu Y, Masica D. The new world in cancer surveillance: accommodating patient privacy and drug safety studies. Presented at the NAACCR; June 2009.

Midkiff KD, Martin RD, Gilsenan AW, Masica D, Andrews EB. New directions in using cancer registry data 5–year results from a patient drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.

Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica N, Andrews EB. Characteristics of patients in a post marketing osteosarcoma surveillance study. Presented at the 34th Meeting of the Scandinavian Sarcoma Group; May 2009.